CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Padsevonil (UCB0942) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03480243
NCT03480243Phase 1Completed
CompareCT.gov

An Open-label, Fixed-sequence Study in Healthy Study Participants to Evaluate the Effect of Coadministered Erythromycin on the Pharmacokinetics and Safety of Padsevonil

UCB Biopharma S.P.R.L.·interventional·Posted Mar 29, 2018·Updated Jul 12, 2021

In Brief

A Phase 1 clinical trial evaluating Padsevonil (UCB0942) and Erythromycin for Pharmacokinetics. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The purpose of this study is to evaluate and compare the Pharmacokinetics (PK) of concomitant administration of Padsevonil (PSL) in the presence and absence of erythromycin in healthy study participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPharmacokinetics
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedMar 29, 2018
Enrollment StartMar 27, 2018
Primary CompletionAug 2, 2018
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 8.3 years ago

Interventions

Padsevonil (UCB0942)drug

* Pharmaceutical Form: film-coated tablet * Route of Administration: Oral use

Erythromycindrug

* Pharmaceutical Form: film-coated tablet * Route of Administration: Oral use